



FOR IMMEDIATE RELEASE

Immgenuity Inc., Announces the Appointment of Internationally known HIV Researcher Dr. Daniel Kuritzkes to its Scientific Advisory Board

Dover, Delaware March 27, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Daniel Kuritzkes has joined its Scientific Advisory Board.

Dr. Kuritzkes, currently Chief of the Division of Infectious Diseases at Brigham and Women’s Hospital in Boston, and Professor of Medicine at Harvard Medical School, has been a leading figure in HIV research for over 30 years, and has been involved in the development of numerous antiviral drugs, including some of the first drugs used to treat HIV. Dr. Kuritzkes has spent decades in HIV research and is a prominent member of the AIDS Clinical Trials Group (ACTG) of the National Institutes of Health (NIH.) He is the past chair of the ACTG executive committee and still serves on many important ACTG committees including the executive committee.

“We are delighted to welcome Dr. Kuritzkes to our Scientific Advisory Board. Dr. Kuritzkes is a highly respected researcher and physician who brings decades of experience in Infectious Diseases and HIV to Immgenuity’s efforts to develop new treatments for HIV that could lead to remission. Furthermore, Dr. Kuritzkes’ expertise in HIV clinical trials, combined with his extensive experience in drug development, will be invaluable as we work to develop new strategies to achieve remission in HIV and address NeuroAIDS”, said Immgenuity CEO, Dr. Sateesh Apte.

“I am excited to join Immgenuity’s Scientific Advisory Board. The company has a strong ethos of innovation and a commitment to developing immunotherapies for HIV that will have a significant impact on public health. I look forward to working with the team to advance the development of the new immunotherapy which has the potential to improve the lives of patients”, said Dr. Kuritzkes.

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity’s immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014

plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.